About 30 results found for searched term "CDK" (0.066 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M5228 | THZ1 | CDK |
| CDK7 inhibitor | ||
| THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7. | ||
| M8902 | CVT-313 | CDK |
| NG26; Cdk2 Inhibitor III | ||
| CVT-313 is a potent and selective inhibitor of CDK2 that prevents neointimal proliferation, which has an IC50 of 0.5 microM in vitro. | ||
| M9910 | CDKI-73 | CDK |
| CDKI73; Asnuciclib; LS-007 | ||
| Cdki-73 (LS-007) is an orally active and highly effective CDK9 inhibitor with Ki values of 4 nM, 4 nM and 3 nM against CDK9, CDK1 and CDK2, respectively. Cdki-73 down-regulates phosphorylation of RNA polymerase II. Cdki-73 is also an inhibitor of Rab11. | ||
| M10379 | BSJ-03-123 | PROTAC |
| PROTAC CDK6 Degrader | ||
| BSJ-03-123 is a novel, potent CDK6-selective small-molecule degrader (PROTAC). | ||
| M10966 | SY-5609 | CDK |
| CDK7-IN-3 | ||
| SY-5609 (CDK7-IN-3) is an orally active, highly selective, noncovalent CDK7 inhibitor with a KD of 0.065 nM. SY-5609 shows poor inhibition on CDK2 (Ki=2600 nM), CDK9 (Ki=960 nM), CDK12 (Ki=870 nM). | ||
| M13422 | Beloranib | Others |
| ZGN-440；CDK-732 | ||
| Beloranib is a methionine aminopeptidase 2 (METAP2) inhibitor. It's an experimental compound candidate for obesity research. | ||
| M13601 | CDK9-IN-2 | CDK |
| CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, with IC50s of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively. | ||
| M21231 | PROTAC CDK9 Degrader-1 | PROTAC |
| PROTAC CDK9 Degrader-1 is a PROTAC linked by Cereblon ligand and CDK ligand and is a selective CDK9 degrader. | ||
| M22026 | CDK2 | Others |
| CDK2 | ||
| M28687 | CDK8-IN-4 | CDK |
| CDK8-IN-4 is an inhibitor of CDK8, with an IC50 of 0.2 nM. | ||
| M28917 | CDK8/19-IN-1 | CDK |
| CDK8/19-IN-1 is a potent, selective and oral bioavailable CDK8/19 dual inhibitor, with IC50s of 0.46 nM, 0.99 nM and 270 nM for CDK8, CDK19 and CDK9, respectively. | ||
| M28989 | CDK8-IN-3 | CDK |
| CDK8-IN-3 is an inhibitor of CDK8. | ||
| M29110 | CDK12-IN-E9 | CDK |
| CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and a non-covalent CDK9 inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC50> 1 μM. | ||
| M29171 | CDK2-IN-4 | CDK |
| CDK2-IN-4 is a potent and selective CDK2 inhibitor with an IC50 of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM). | ||
| M29353 | CDK1-IN-2 | CDK |
| CDK1-IN-2 is a CDK1 inhibitor (IC50: 5.8 μM). | ||
| M29364 | CDK12-IN-3 | CDK |
| CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC50 of 491 nM in enzymatic assay. | ||
| M30104 | Cdk1/2 Inhibitor III | CDK |
| Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor, with an IC50 of 2.1 μM for CDK1/cyclin B. | ||
| M31195 | CDK1/2/4-IN-1 | CDK |
| CDK1/2/4-IN-1 is a potent CDK inhibitor with IC50 values of 1.47, 0.78 and 0.87 μM for CDK1, CDK2 and CDK4, respectively. CDK1/2/4-IN-1 arrests cell cycle at G2/M phase and induces apoptosis. CDK1/2/4-IN-1 elevates Bax, caspase-3, P53 levels and decreases Bcl-2 level. | ||
| M31196 | CDK12-IN-2 | CDK |
| CDK12-IN-2 is a potent, selective and nanomolar CDK12 inhibitor (IC50=52 nM). CDK12-IN-2 is also a strong CDK13 inhibitor due to CDK13 is the closest homologue of CDK12. CDK12-IN-2 inhibits the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II. CDK12-IN-2 can be used an excellent chemical probe for functional studies of CDK12. | ||
| M31197 | CDK2/4/6-IN-1 | CDK |
| CDK2/4/6-IN-1 is a CDK2/4/6 inhibitor with IC50 values of 2.5, 23.7 and 44.3 nM for CDK2, CDK4 and CDK6, respectively. CDK2/4/6-IN-1 can be used in cancer research. | ||
| M31198 | CDK4/6-IN-14 | CDK |
| CDK4/6-IN-14 is a potent and highly selective CDK4 and CDK6 (CDK) inhibitor with IC50s of 10 nM and 16 nM, respectively. CDK4/6-IN-14 exhibits more than 60-fold selectivity over CDKs 1, 2, 7, and 9, and shows high selectivity among other 205 kinases. | ||
| M31199 | CDK-IN-2 | CDK |
| CDK-IN-2 is a potent and specific CDK9 inhibitor with IC50 of <8 nM. | ||
| M31276 | PROTAC CDK2/9 Degrader-1 | PROTAC |
| PROTAC CDK2/9 Degrader-1 is a potent dual degrader for CDK2 (DC50=62 nM) and CDK9 (DC50=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC50=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with Cereblon ligand. | ||
| M41300 | CDK8-IN-13 | Apoptosis |
| CDK8-IN-13 is a potent, selective and orally active CDK8 inhibitor with an IC50 value of 51.9 nM. | ||
| M41424 | CDK4/6-IN-17 | CDK |
| CDK4/6-IN-17 is an orally active CDK4/6 inhibitor with IC50 ranging of 10-100 nM in BE(2) cells. | ||
| M41425 | CDK7-IN-25 | CDK |
| CDK7-IN-25 (CY-16-1) is a CDK-7 inhibitor (IC50<1nM) that can be used in cancer research. | ||
| M41430 | CDK2-IN-19 | CDK |
| CDK2-IN-19 is a selective and orally active CDK2 inhibitor (Ki: 0.18 nM). | ||
| M41431 | CDK4-IN-2 | CDK |
| CDK4-IN-2 is a CDK4 inhibitor, with Ki and IC50 values of <10 nM. | ||
| M41433 | PROTAC CDK9 degrader-6 | CDK |
| PROTAC CDK9 degrader-6 is a PROTAC targeting to CDK9 sepcifically. | ||
| M41434 | PROTAC CDK9 degrader-7 | CDK |
| PROTAC CDK9 degrader-7 is a PROTAC targeting to CDK9 sepcifically. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
